Compare AbbVie Inc (ABBV) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Mercadolibre Inc — how do they compare? AbbVie Inc trades at $253.55 (market cap $449.91B), while Mercadolibre Inc trades at $1,807.68 (market cap $91.94B). The key difference: AbbVie Inc is far larger — about 4.9× Mercadolibre Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| ABBV | MELI | |
|---|---|---|
Market Cap | $449.91B | $91.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $2.51K |
52-Week Low | $184.85 | $1.55K |
Enterprise Value | $513.38B | $98.83B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
MercadoLibre (MELI) trades at $1,813.61, up 2.85% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with robust revenue growth of 49% in Q1 2026 and expanding cash flow generation. Analyst consensus remains strongly positive with a $2,230 price target, though margin compression from aggressive investments presents near-term challenges.
MELI offers significant growth potential as Latin America's e-commerce leader, but faces execution risks from margin pressure and legal investigations. The stock trades at premium valuations (P/E 47.66) requiring sustained high growth to justify current levels. Institutional support remains strong with 71.9% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
